Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$225.28
-1.5%
$231.30
$150.89
$250.74
$14.27B0.41807,098 shs446,120 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.78
-0.3%
$71.29
$31.77
$84.94
$13.51B1.022.59 million shs2.12 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$30.86
+6.6%
$25.04
$19.05
$32.56
$3.54B0.721.96 million shs2.82 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.54
+3.3%
$18.46
$13.83
$30.98
$13.18B-1.254.96 million shs4.49 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+7.38%+4.82%+24.99%+23.14%+27.00%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+8.88%-17.50%-9.49%+21.55%-37.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$225.28
-1.5%
$231.30
$150.89
$250.74
$14.27B0.41807,098 shs446,120 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.78
-0.3%
$71.29
$31.77
$84.94
$13.51B1.022.59 million shs2.12 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$30.86
+6.6%
$25.04
$19.05
$32.56
$3.54B0.721.96 million shs2.82 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.54
+3.3%
$18.46
$13.83
$30.98
$13.18B-1.254.96 million shs4.49 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+7.38%+4.82%+24.99%+23.14%+27.00%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+8.88%-17.50%-9.49%+21.55%-37.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.95
Moderate Buy$291.5629.42% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$87.7127.53% Upside
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.50
Strong Buy$34.0010.17% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.59
Moderate Buy$27.5857.26% Upside

Current Analyst Ratings Breakdown

Latest CPRX, ASND, BBIO, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$30.00 ➝ $23.00
5/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetNeutral$17.00 ➝ $16.00
4/29/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetBuy$95.00 ➝ $102.00
4/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingOutperform$106.00
4/27/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$100.00
4/21/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingSell (D-)
4/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$262.00 ➝ $292.00
4/9/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform$273.00
4/9/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageOutperform$100.00
4/8/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Initiated CoverageBuy
4/8/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UpgradeModerate Buy
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.25N/AN/A($2.97) per share-75.85
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.82N/AN/A($10.77) per share-6.39
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$588.99M6.41$3.12 per share9.90$7.76 per share3.98
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M-$4.40N/A21.60N/A-30.85%N/A-19.63%5/7/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.78N/A146.34N/A-144.39%N/A-74.43%5/7/2026 (Estimated)
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.6918.2610.020.9436.39%36.47%31.85%5/11/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/A

Latest CPRX, ASND, BBIO, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$0.64N/AN/AN/A$148.18 millionN/A
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21N/AN/AN/A$362.56 millionN/A
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70N/AN/AN/A$178.64 millionN/A
4/30/2026Q1 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A
2/24/2026Q4 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million
2/23/2026Q4 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.22-$0.29-$0.07-$0.29$75.47 millionN/A
2/12/2026Q4 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$0.06-$0.64-$0.58-$0.65$285.35 million$290.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.76
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
2.77
2.68
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.08
5.82
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
7.41
9.87

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.81 million167.94 millionOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.35 million109.42 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110776.16 million128.05 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next?
Summit Therapeutics Shock Move Hits Nasdaq Futures

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$225.28 -3.43 (-1.50%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$225.29 +0.01 (+0.00%)
As of 05/5/2026 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$68.78 -0.21 (-0.30%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$69.12 +0.34 (+0.50%)
As of 05/5/2026 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$30.86 +1.92 (+6.63%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$31.20 +0.34 (+1.10%)
As of 05/5/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.54 +0.56 (+3.30%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$17.47 -0.07 (-0.40%)
As of 05/5/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.